China Pharma Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2012
Filed with the SEC on Aug 14, 2012 and accepted by EDGAR at Aug 14, 2012, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-04-01 to 2012-06-30 | $14.6m | us-gaap:Revenues |
| Revenue | 6 months2012-01-01 to 2012-06-30 | $30.7m | us-gaap:Revenues |
| Cost of revenue | 3 months2012-04-01 to 2012-06-30 | $10.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2012-01-01 to 2012-06-30 | $21.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2012-04-01 to 2012-06-30 | $4.1m | us-gaap:GrossProfit |
| Gross profit | 6 months2012-01-01 to 2012-06-30 | $9.4m | us-gaap:GrossProfit |
| Operating income | 3 months2012-04-01 to 2012-06-30 | $2.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2012-01-01 to 2012-06-30 | $5.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-04-01 to 2012-06-30 | −$78.5k | us-gaap:InterestExpense |
| Interest expense | 6 months2012-01-01 to 2012-06-30 | −$156.0k | us-gaap:InterestExpense |
| Income tax | 3 months2012-04-01 to 2012-06-30 | −$372.9k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2012-01-01 to 2012-06-30 | −$903.5k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-04-01 to 2012-06-30 | $1.8m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2012-04-01 to 2012-06-30 | $0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2012-01-01 to 2012-06-30 | $0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2012-04-01 to 2012-06-30 | $0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2012-01-01 to 2012-06-30 | $0.10 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2012-01-01 to 2012-06-30 | $1.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2012-01-01 to 2012-06-30 | −$67.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2012-06-30 | $4.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-06-30 | $118.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2012-06-30 | $164.9m | us-gaap:Assets |
| Current liabilities | At period end2012-06-30 | $16.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-06-30 | $16.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-06-30 | $148.2m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2012-06-30 | 43,529,557 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001010549-12-000896. Last ingested by Listed: Oct 30, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.